Schroder Investment Management Group
BMRN icon

Schroder Investment Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Schroder Investment Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-56,334
Closed -$3.18M – 1181
2026
Q1 		$3.18M Sell
56,334
-111,191
-66% -$6.48M ﹤0.01% 847
2025
Q4 		$9.96M Sell
167,525
-3,937
-2% -$214K 0.01% 636
2025
Q3 		$9.29M Buy
171,462
+79,181
+86% +$4.53M 0.01% 676
2025
Q2 		$5.07M Sell
92,281
-75,799
-45% -$4.46M ﹤0.01% 763
2025
Q1 		$11.9M Sell
168,080
-50,884
-23% -$3.42M 0.01% 608
2024
Q4 		$14.4M Buy
218,964
+89,515
+69% +$6M 0.01% 586
2024
Q3 		$9.1M Sell
129,449
-100,150
-44% -$8.37M 0.01% 679
2024
Q2 		$18.9M Sell
229,599
-20,494
-8% -$1.71M 0.02% 481
2024
Q1 		$21.8M Sell
250,093
-20,324
-8% -$1.82M 0.03% 471
2023
Q4 		$26.1M Buy
270,417
+141,694
+110% +$12.5M 0.03% 426
2023
Q3 		$11.4M Sell
128,723
-10,082
-7% -$897K 0.02% 580
2023
Q2 		$12M Sell
138,805
-1,054
-0.8% -$99.2K 0.02% 588
2023
Q1 		$13.6M Buy
139,859
+876
+0.6% +$90.8K 0.02% 562
2022
Q4 		$14.4M Buy
138,983
+30,867
+29% +$2.9M 0.02% 543
2022
Q3 		$9.16M Buy
108,116
+95,959
+789% +$8.54M 0.02% 630
2022
Q2 		$1.01M Buy
12,157
+5,194
+75% +$414K ﹤0.01% 1071
2022
Q1 		$542K Buy
6,963
+2,041
+41% +$171K ﹤0.01% 1211
2021
Q4 		$435K Buy
4,922
+95
+2% +$7.84K ﹤0.01% 1136
2021
Q3 		$373K Sell
4,827
-283
-6% -$22.3K ﹤0.01% 1246
2021
Q2 		$427K Buy
5,110
+1,170
+30% +$92.7K ﹤0.01% 1242
2021
Q1 		$298K Buy
3,940
+77
+2% +$6.29K ﹤0.01% 1292
2020
Q4 		$338K Sell
3,863
-78
-2% -$6.18K ﹤0.01% 1249
2020
Q3 		$295K Sell
3,941
-342
-8% -$34.6K ﹤0.01% 1148
2020
Q2 		$528K Sell
4,283
-535
-11% -$53.2K ﹤0.01% 995
2020
Q1 		$398K Buy
+4,818
New +$415K ﹤0.01% 1011
2013
Q3 		– Sell
-13,644
Closed -$761K – 1517
2013
Q2 		$761K Buy
+13,644
New +$850K ﹤0.01% 1044

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Schroder Investment Management Group's BMRN Position: Q2 2026 in Review

Schroder Investment Management Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 56,334 shares — an estimated $3.18M sold.

Schroder Investment Management Group first reported a position in BMRN in Q2 2013 and held it in 26 quarters. The position peaked at $26.1M in Q4 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Schroder Investment Management Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 56,334 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.18M.
  • Schroder Investment Management Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Schroder Investment Management Group's BioMarin Pharmaceuticals position peaked at $26.1M in Q4 2023.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.